MedTrace Logo

A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes

NCT00961324 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2017-10-09

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this clinical trial is to evaluate the variability in the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.

Conditions

Interventions

DRUG

insulin degludec

The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days

DRUG

insulin glargine

The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-27
Primary Completion
2009-10-26
Completion
2009-10-26

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00961324 on ClinicalTrials.gov